OncoSec Medical - ONCS Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings or view top-rated stocks.

OncoSec Medical's stock was trading at $1.68 on January 1st, 2023. Since then, ONCS shares have increased by 23.8% and is now trading at $2.08.
View the best growth stocks for 2023 here.

OncoSec Medical saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 443,400 shares, an increase of 1,853.3% from the February 13th total of 22,700 shares. Based on an average daily volume of 2,000,000 shares, the short-interest ratio is currently 0.2 days. Approximately 26.2% of the company's shares are sold short.
View OncoSec Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 13th 2023.
View our ONCS earnings forecast.

OncoSec Medical Incorporated (NASDAQ:ONCS) posted its earnings results on Tuesday, December, 14th. The biotechnology company reported ($5.50) EPS for the quarter, topping the consensus estimate of ($8.14) by $2.64.

Shares of OncoSec Medical reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

OncoSec Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.81%), Two Sigma Investments LP (0.71%), Salzhauer Michael (0.70%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano and Yuhang Zhao.
View institutional ownership trends.

Shares of ONCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONCS stock can currently be purchased for approximately $2.08.

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $6.18 million. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($15.2865) on an earnings per share basis.

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.